SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jim Bishop who wrote (99469)1/14/2002 10:30:30 AM
From: Taki  Read Replies (2) of 150070
 
MDCH. .026x .034.News out.
Meditech Cold Sore -- HSV-1 -- Clinical Trial's Set to Commence at Boston

University

Health/Medical Writers

SCOTTSDALE, Ariz.--(BW HealthWire)--Jan. 14, 2002--Meditech
Pharmaceuticals Inc. (OTC BB: MDCH) Monday announced that it has
received final IRB (Independent Review Board) approval for
commencement of its cold sore (HSV-1) clinical trials at Boston
University.
The Web site address for the clinical trials is
icrc.bumc.bu.edu. People who wish to qualify and enroll for
the study will be able to do so at that Web site beginning the week of
Jan. 28, 2002.
Meditech shareholders are being asked not to apply for admission
to the study so as to preserve the complete and total impartiality of
the study. The company will make arrangements to accommodate its
shareholders separately from the study.
Meditech Chairman and Chief Executive Officer Gerald Kern stated,
"We are very pleased that the study is about to begin. To ensure that
the results of this study be totally independent, we have decided not
to enroll Meditech shareholders, employees or affiliates as patients.
"We will arrange to accommodate them outside of the clinical
trials. Details of the shareholder/affiliate program will be posted on
the company's Web site -- www.mdch.net."
Separately, Meditech has been notified by the United States PTO
(Patent and Trademark Office) that the Zilex trademark has been
allowed for use.
Meditech is a drug development company focused on the development
of human, veterinary and agricultural antimicrobial agents. Meditech
was founded in 1982 as Medical Technology Corporation of America and
went public via an IPO in 1983.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News